[go: up one dir, main page]

BR9814611A - Polipeptìdeos modificados dependentes de vitamina k - Google Patents

Polipeptìdeos modificados dependentes de vitamina k

Info

Publication number
BR9814611A
BR9814611A BR9814611-4A BR9814611A BR9814611A BR 9814611 A BR9814611 A BR 9814611A BR 9814611 A BR9814611 A BR 9814611A BR 9814611 A BR9814611 A BR 9814611A
Authority
BR
Brazil
Prior art keywords
vitamin
dependent
modified polypeptides
polypeptides
mammals
Prior art date
Application number
BR9814611-4A
Other languages
English (en)
Inventor
Gary L Nelsestuen
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BR9814611A publication Critical patent/BR9814611A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: <B>"POLIPEPTìDEOS MODIFICADOS DEPENDENTES DE VITAMINA K"<D>. A invenção proporciona polipeptídeos dependentes de vitamina K com afinidade de ligação de membrana intensificada. Esses polipeptídeos podem ser usados para modular a formação de coágulos em mamíferos. Métodos de modulação da formação de coágulos em mamíferos também são descritos.
BR9814611-4A 1997-10-23 1998-10-20 Polipeptìdeos modificados dependentes de vitamina k BR9814611A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides
PCT/US1998/022152 WO1999020767A1 (en) 1997-10-23 1998-10-20 Modified vitamin k-dependent polypeptides

Publications (1)

Publication Number Publication Date
BR9814611A true BR9814611A (pt) 2000-10-03

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814611-4A BR9814611A (pt) 1997-10-23 1998-10-20 Polipeptìdeos modificados dependentes de vitamina k

Country Status (30)

Country Link
US (1) US6017882A (pt)
EP (2) EP1090128B1 (pt)
JP (1) JP4276379B2 (pt)
KR (1) KR20010031370A (pt)
CN (1) CN1246462C (pt)
AP (1) AP2000001811A0 (pt)
AR (2) AR020048A1 (pt)
AT (1) ATE390486T1 (pt)
AU (1) AU749279C (pt)
BR (1) BR9814611A (pt)
CA (1) CA2307175C (pt)
DE (1) DE69839313T2 (pt)
DK (1) DK1090128T3 (pt)
EA (1) EA200000449A1 (pt)
ES (2) ES2303362T3 (pt)
HR (1) HRP20000234A2 (pt)
HU (1) HU225993B1 (pt)
ID (1) ID26330A (pt)
IL (1) IL135603A0 (pt)
IS (1) IS5449A (pt)
MY (1) MY136336A (pt)
NO (1) NO20002025L (pt)
NZ (1) NZ504114A (pt)
PL (1) PL194194B1 (pt)
PT (1) PT1090128E (pt)
SG (1) SG105547A1 (pt)
TR (1) TR200001105T2 (pt)
TW (1) TW587081B (pt)
WO (1) WO1999020767A1 (pt)
ZA (1) ZA989597B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
CA2455170A1 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1370649A1 (en) * 2001-03-02 2003-12-17 T.A.C. Thrombosis and Coagulation AB Protein c variants
WO2003073980A2 (en) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c variants
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
EP1611236A1 (en) 2003-03-18 2006-01-04 Novo Nordisk Health Care AG Method for the production of gla-residue containing serine proteases
ES2327044T3 (es) * 2003-03-20 2009-10-23 Bayer Healthcare Llc Variantes de fvii o fviia.
WO2004111242A1 (en) * 2003-06-19 2004-12-23 Maxygen Holdings Ltd. FACTOR VII OR VIIa GLA DOMAIN VARIANTS
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
EP2275432A1 (en) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration of factor VII solutions to remove virus
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
EP1924689B1 (en) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Hydrophobic interaction chromatography purification of factor vii polypeptides
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
CA2683443A1 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
HRP20171375T1 (hr) 2007-12-27 2017-12-15 Baxalta GmbH Postupci s kulturama stanica
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
CN102686603B (zh) * 2009-12-14 2014-12-17 国立大学法人北海道大学 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
NZ703148A (en) 2012-07-25 2016-08-26 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
ATE390486T1 (de) 2008-04-15
AP2000001811A0 (en) 2000-06-30
WO1999020767A1 (en) 1999-04-29
TR200001105T2 (tr) 2000-09-21
AR035786A2 (es) 2004-07-14
DE69839313T2 (de) 2009-04-16
ID26330A (id) 2000-12-14
NO20002025L (no) 2000-06-19
HUP0102257A3 (en) 2003-09-29
NZ504114A (en) 2002-10-25
DE69839313D1 (de) 2008-05-08
CN1283231A (zh) 2001-02-07
ES2496104T3 (es) 2014-09-18
SG105547A1 (en) 2004-08-27
CA2307175C (en) 2009-04-14
EA200000449A1 (ru) 2000-12-25
AU2702499A (en) 1999-05-10
CN1246462C (zh) 2006-03-22
AU749279C (en) 2004-09-16
KR20010031370A (ko) 2001-04-16
AU749279B2 (en) 2002-06-20
EP1676919B1 (en) 2014-07-23
TW587081B (en) 2004-05-11
PL194194B1 (pl) 2007-05-31
HU225993B1 (en) 2008-02-28
HUP0102257A2 (hu) 2001-09-28
JP4276379B2 (ja) 2009-06-10
NO20002025D0 (no) 2000-04-18
ZA989597B (en) 1999-04-23
PL340284A1 (en) 2001-01-29
CA2307175A1 (en) 1999-04-29
DK1090128T3 (da) 2008-06-23
EP1090128A1 (en) 2001-04-11
ES2303362T3 (es) 2008-08-01
EP1090128B1 (en) 2008-03-26
EP1676919A1 (en) 2006-07-05
US6017882A (en) 2000-01-25
IL135603A0 (en) 2001-05-20
PT1090128E (pt) 2008-04-17
HRP20000234A2 (en) 2001-08-31
MY136336A (en) 2008-09-30
IS5449A (is) 2000-04-14
JP2001520042A (ja) 2001-10-30
AR020048A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
BR9814611A (pt) Polipeptìdeos modificados dependentes de vitamina k
EP2085471A3 (en) Modified factor VIIA polypeptides
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
TR200100056T2 (tr) Nörotrofik faktörler
BR9809279A (pt) Procedimento para produção de uma fração de blocos g e/ou blocos m a partir de alginato
FI974141A7 (fi) Viestin sisällön hyödyntäminen
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69818450D1 (de) Im wesentlichen reines zonulin als physiologischer modulator von &#34;tight junctions&#34; bei säugern
PL336470A1 (en) Mammalian cytokin-like factor 7
DE69505804D1 (de) Afamin: ein menschliches serum albumin ähnliches protein
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DK0984983T3 (da) Modulatorer af intracellulære inflammations-, celledöds- og celleoverlevelsesforlöb indeholdende et CARD- og et kinasedomæne
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
EP1009422A4 (en) STRUCTURE OF THE ANKYRINE BONDING POINT OF AN ALPHA-NA, K-ATPASE
WO2000008146A3 (de) Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
ATE329035T1 (de) Cytoplasmische tyrosin kinase
AU132015S (en) Pants
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO, TENDO POR BASE OS ARTIGOS 8O, 13 E 25 DA LEI 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time